4-[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]Piperidine | 265108-39-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]Piperidine
• 英文别名: 4-(oxan-4-yloxymethyl)piperidine
• CAS: 265108-39-2
• 化学式: C₁₁H₂₁NO₂
• 分子量: 199.293
• InChiKey: IKEPWJORLCFCIG-UHFFFAOYSA-N

物化性质

• 沸点：
  298.1±25.0 °C(Predicted)
• 密度：
  1.02±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]Piperidine 、 5-(3-Bromophenyl)-7-(6-chloropyridazin-3-yl)pyrido[2,3-d]pyrimidin-4-amine 以 二甲基亚砜 为溶剂， 生成 5-(3-Bromo-phenyl)-7-{6-[4-(tetrahydro-pyran-4-yloxymethyl)-piperidin-1-yl]-pyridazin-3-yl}-pyrido[2,3-d]pyrimidin-4-ylamine
  参考文献：
  名称：

  Adenosine kinase inhibitors: polar 7-Substitutent of pyridopyrimidine derivatives improving their locomotor selectivity

  摘要：

  We have discovered that polar 7-substituents of pyridopyrimidine derivatives affect not only whole cell AK inhibitory potency. but also selectivity in causing locomotor side effects in vivo animal models. We have identified compound, 1o, which has potent whole cell AK inhibitory potency, analgesic activity and minimal reduction of locomotor activity. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00642-5

文献信息

• [EN] 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSES DE 4-AMINOPYRIDO[2,3-D]PYRIMIDINE A DISUBSTITUTION 5,7
  申请人：ABBOTT LAB

  公开号：WO2000023444A1

  公开（公告）日：2000-04-27

  A method of inhibiting adenosine kinase by administering one of more compounds of formula (I), wherein R?1, R2, R3 and R4¿ are defined, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above in combination with a pharmaceutically acceptable carrier, and a method of treating cerebral ischemia, epilepsy, nociperception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, a process for preparing said compounds, and compounds having the above formula wherein R?1, R2, R3 and R4¿ are separately defined.

  一种通过给予式(I)中的一个或多个化合物来抑制腺苷激酶的方法，其中R1、R2、R3和R4被定义，以及包含上述化合物的治疗有效量与药学可接受载体组合的制药组合物，以及一种治疗哺乳动物的脑缺血、癫痫、疼痛感知、炎症和败血症的方法，包括给予哺乳动物上述化合物的治疗有效量，制备上述化合物的方法以及具有上述式中R1、R2、R3和R4分别被定义的化合物。